We use privacy-friendly analytics. Read our privacy policy.DNT/GPC detected: tracking stays off.
Evidence-first comparison
Berberine vs Cinnamon
Primary decision context: Metabolic-health research where evidence strength and medication-interaction context matter more than shared blood-sugar marketing.
Quick verdict
Evidence edge: Berberine
Berberine has the stronger profile-level evidence grade in the canonical records (A vs B). That is an overall evidence signal, not proof that it is better for every outcome.
Berberine and cinnamon are both discussed in metabolic-health searches, but their human evidence, preparations, doses, and interaction burdens are not interchangeable. This page compares the structured records directly.
The table below is populated from each ingredient’s canonical runtime record. Missing fields stay visibly missing rather than being filled with mechanism-derived assumptions.
Choose Berberine if…
•Its human-evidence summary directly addresses the outcome you are researching.
•Its studied dose and formulation context match the form you are actually evaluating.
•You have reviewed its documented safety and interaction constraints rather than choosing on marketing claims alone.
Choose Cinnamon if…
•Its human-evidence summary directly addresses the outcome you are researching.
•Its studied dose and formulation context match the form you are actually evaluating.
•You have reviewed its documented safety and interaction constraints rather than choosing on marketing claims alone.
Neither may be appropriate if…
The comparison itself does not clear the decision bar
•Neither option has adequate human outcome evidence for the actual decision context: Metabolic-health research where evidence strength and medication-interaction context matter more than shared blood-sugar marketing.
•The available comparison is driven mainly by mechanism, chemistry, or marketing rather than replicated human outcomes.
•A contraindication, medication interaction, pregnancy concern, or other safety constraint makes unsupervised use inappropriate.
•The relevant studied formulation or dose is materially different from the product or form being considered.
Berberine vs Cinnamon: evidence, dose, and safety
This table scrolls horizontally on small screens. Use Tab to focus the table region, then scroll with arrow keys or touch.
Berberine vs Cinnamon: evidence, dose, and safety
Dimension
Berberine
Cinnamon
Evidence strength
A
B
Human evidence
Not available in the canonical record.
Not available in the canonical record.
Studied dose / dose context
capsule or standardized extract
1-3 g/day powder or equivalent extract
Forms / preparation
Not available in the canonical record.
Not available in the canonical record.
Safety
Safety evidence: gastrointestinal adverse effects are most commonly reported. Avoid during pregnancy, breastfeeding, and in infants; repeated human dosing inhibited CYP2D6, CYP2C9, and CYP3A4, and a clinical cyclosporine interaction is documented, so medication review is important.
Safety evidence: gastrointestinal adverse effects are most commonly reported. Avoid during pregnancy, breastfeeding, and in infants; repeated human dosing inhibited CYP2D6, CYP2C9, and CYP3A4, and a clinical cyclosporine interaction is documented, so medication review is important.
Cinnamon is the aromatic bark of Cinnamomum trees; this profile covers Cinnamomum verum, the Ceylon or 'true' cinnamon, which is low in coumarin compared with the more common cassia types. Cinnamon has been studied for blood sugar and lipids: a systematic review and meta-analysis of type 2 diabetes trials found that cinnamon lowered fasting glucose and improved cholesterol and triglycerides, but did not significantly change HbA1c, and the trials were inconsistent and mostly used cassia rather than Ceylon cinnamon. High intake of the coumarin in cassia can stress the liver, a concern that is mu
Read the full profile →Mechanism differences are shown as mechanism context, not as proof of different health benefits. Comparison conclusions should follow human outcome evidence, safety, dose, and formulation data where those fields are available.
Safety first · Harm reduction
This information is educational and not medical advice. Start low, avoid risky combinations, and consult a licensed clinician before making health decisions—especially if you use medications, have diagnosed conditions, or are pregnant/breastfeeding.
Learn how we evaluate confidence, safety, and intensity on the methodology page.